non fda approved glp 1 restricts GLP-1 ingredients in non-approved compounded drugs | FDA posted on the topic Can You Trust Compounded GLP-1s?

Insulin resistance and blood sugar changes Estrogen enhances insulin sensitivity

Tetzlaff ED, Correa AM, Komaki R, Swisher S , Maru D, Ross W, Ajani JA

Russ J Dev Biol 37(2):113118

According to FDA prescribing information, these include: Nausea (occurring in 1544% of patients depending on the specific agent and dose) Vomiting (524% of patients) Diarrhea (821% of patients) Constipation (1024% of patients) Abdominal pain or discomfort (514% of patients) These symptoms typically emerge during dose initiation or escalation and often diminish over several weeks as the body adapts

39 Another study that compared intravenous, intrathecal, and intranasal administration of exosomes found that intranasal administration was best for delivery to the brain

New York, NY: Biometrics Research Department, New York State Psychiatric Institute (1995)